Novartis Ends Phase 2 Fabhalta Trial for Lupus Kidney Disease

Novartis ended its Phase 2 trial of Fabhalta (iptacopan) for lupus nephritis for strategic reasons after the final patient completed the last visit in Part 1. Fabhalta is an oral Factor B inhibitor. The study tested it alongside standard-of-care treatment for lupus nephritis, an inflammatory kidney condition associated with lupus. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.